199 related articles for article (PubMed ID: 31018252)
1. Chemoradiation induces epithelial-to-mesenchymal transition in esophageal adenocarcinoma.
Steins A; Ebbing EA; Creemers A; van der Zalm AP; Jibodh RA; Waasdorp C; Meijer SL; van Delden OM; Krishnadath KK; Hulshof MCCM; Bennink RJ; Punt CJA; Medema JP; Bijlsma MF; van Laarhoven HWM
Int J Cancer; 2019 Nov; 145(10):2792-2803. PubMed ID: 31018252
[TBL] [Abstract][Full Text] [Related]
2. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
4. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
[TBL] [Abstract][Full Text] [Related]
5. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.
Ebbing EA; van der Zalm AP; Steins A; Creemers A; Hermsen S; Rentenaar R; Klein M; Waasdorp C; Hooijer GKJ; Meijer SL; Krishnadath KK; Punt CJA; van Berge Henegouwen MI; Gisbertz SS; van Delden OM; Hulshof MCCM; Medema JP; van Laarhoven HWM; Bijlsma MF
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2237-2242. PubMed ID: 30670657
[TBL] [Abstract][Full Text] [Related]
6. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
7. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
[TBL] [Abstract][Full Text] [Related]
8. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).
Hoeppner J; Lordick F; Brunner T; Glatz T; Bronsert P; Röthling N; Schmoor C; Lorenz D; Ell C; Hopt UT; Siewert JR
BMC Cancer; 2016 Jul; 16():503. PubMed ID: 27435280
[TBL] [Abstract][Full Text] [Related]
9. Predicting outcomes in esophageal adenocarcinoma following neoadjuvant chemoradiation: Interactions between tumor response and survival.
Solomon D; Deeb AL; Tarabine K; Xie Y; Mazzola E; Zhao L; Hammer MM; Jaklitsch MT; Swanson SJ; Bueno R; Wee JO
J Thorac Cardiovasc Surg; 2024 Jul; 168(1):278-289.e4. PubMed ID: 37967764
[TBL] [Abstract][Full Text] [Related]
10. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy.
Nieman DR; Peyre CG; Watson TJ; Cao W; Lunt MD; Lada MJ; Han MS; Jones CE; Peters JH
Ann Thorac Surg; 2015 Jan; 99(1):277-83. PubMed ID: 25442991
[TBL] [Abstract][Full Text] [Related]
12. Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation.
Harada K; Wu CC; Wang X; Mizrak Kaya D; Amlashi FG; Iwatsuki M; Blum Murphy MA; Maru DM; Weston B; Lee JH; Rogers JE; Thomas I; Shanbhag N; Bhutani MS; Hofstetter WL; Nguyen QN; Ajani JA
Ann Surg; 2020 Aug; 272(2):311-318. PubMed ID: 32675544
[TBL] [Abstract][Full Text] [Related]
13. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
14. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
15. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
16. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
19. In vitro and ex vivo vanadium antitumor activity in (TGF-β)-induced EMT. Synergistic activity with carboplatin and correlation with tumor metastasis in cancer patients.
Petanidis S; Kioseoglou E; Domvri K; Zarogoulidis P; Carthy JM; Anestakis D; Moustakas A; Salifoglou A
Int J Biochem Cell Biol; 2016 May; 74():121-34. PubMed ID: 26916505
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
